Introduction: Non-clinical seizure liability studies typically aim to: 1) confirm the nature of EEG activity during abnormal clinical signs, 2) identify premonitory clinical signs, 3) measure plasma levels at seizure onset, 4) demonstrate that drug-induced seizures are self-limiting, 5) confirm that conventional drugs (e.g. diazepam) can treat drug-induced seizures and 6) confirm the no observed adverse effect level (NOAEL) at EEG. Our aim was to originally characterize several of these items in a three species comparative study. Methods: Cynomolgus monkey, Beagle dog and Sprague-Dawley rat with EEG telemetry transmitters were used to obtain EEG using the 10-20 system. Pentylenetetrazol (PTZ) was used to determine seizure threshold or as a positive seizurogenic agent. Clinical signs were recorded and premonitory signs were evaluated. In complement, other pharmacological agents were used to illustrate various safety testing strategies. Results: Intravenous PTZ doses required to induce clonic convulsions were 36.1 (3.8), 56.1 (12.7) and 49.4 (11.7) mg/kg, in Beagle dogs, cynomolgus monkeys and Sprague-Dawley rats, respectively. Premonitory clinical signs typically included decreased physical activity, enhanced physiological tremors, hypersalivation, ataxia, emesis (except in rats) and myoclonus. In Sprague-Dawley rats, amphetamine (PO) increased high (approximately 40-120 Hz), and decreased low (1-14 Hz) frequencies. In cynomolgus monkeys, caffeine (IM) increased power in high (14-127 Hz), and attenuated power in low (1-13 Hz) frequencies. In the rat PTZ infusion seizure threshold model, yohimbine (SC and IV) and phenobarbital (IP) confirmed to be reliable positive controls as pro-and anticonvulsants, respectively. Discussion: Telemetry video-EEG for seizure liability investigations was characterized in three species. Rats represent a first-line model in seizure liability assessments. Beagle dogs are often associated with overt susceptibility to seizure and are typically used in seizure liability studies only if required by regulators. Non-human primates represent an important model in seizure liability assessments given similarities to humans and a high translational potential.
Introduction
Convulsions observed in pre-clinical studies are often the first indication of the seizure potential of a compound in development. In this context, recognition of seizure activity and any premonitory signs thereof (Scaramelli et al., 2009) obtained by means of a reliable method can be crucial, as an estimated 6.1% of new-onset seizures are drugrelated (Pesola & Avasarala, 2002) . Seizure detection is also of increasing importance, due to the multitude of commercially available drugs known to lower seizure threshold and/or increase the incidence of seizures in patients taking these agents. Several widely used antibiotics, Electroencephalography (EEG) can be applied in both non-clinical studies and clinical trials to assess adverse drug effects on the central nervous system (CNS), including detection of seizure activity (Authier et al., 2009; Leiser, Dunlop, Bowlby, & Devilbiss, 2011) . Although convulsions, defined as involuntary contractions of voluntary muscles, can typically be identified by clinical observation, confirmation of seizure activity, which by definition is due to abnormal brain electrophysiological activity, requires the review of EEG. Morphological characteristics suggestive of altered seizure threshold or frank seizure, including increased synchrony, repetitive sharp waves, slow-wave complexes or spike trains, can be detected by EEG monitoring (Aiello & Mays, 1998) . Sharp waves are defined as EEG transients with a duration of 70 to 200 ms, whereas spikes have a duration of 20 to 70 ms (Stern, 2013) . In humans, EEG typically reveals bursts of low amplitude, rhythmic and synchronized activity prior to seizure onset (Niederhauser, Esteller, Echauz, Vachtsevanos, & Litt, 2003) . These observations are also considered as typical present in animals. Paroxysmal EEG activity, which may be premonitory to seizure (Authier et al., 2009) , is useful in neurological safety assessments (Authier et al., 2009) . When seizures are observed in non-clinical studies, characterization of the seizure and the pharmacology surrounding the event are valuable to clinicians subsequently conducting clinical trials, as information regarding the type of seizure, the timing relative to drug administration, the maximum plasma drug concentration (C max ), precursor clinical signs and dose dependency will provide the clinicians with the necessary tools to properly monitor their patients (Avila, 2011) . Without EEG monitoring during non-clinical studies, seizures are typically characterized only by their overt clinical signs. Clonic convulsions are defined as rapid alternation between muscular contraction and relaxation, whereas a continuous muscular contraction characterizes tonic convulsions (Blood & Studdert, 1988) . Myoclonus, occasionally referred to as myoclonic jerks, is characterized by the involuntary jerking of a muscle or group of muscles (National Institute of Neurological Disorders and Stroke, 2012a, 2012b) . A study conducted by Scaramelli et al. (2009) revealed that 39 out of 100 patients reported premonitory signs, including behavioral and cognitive changes, prior to seizure onset. Humans may report confusion prior to a seizure but such a qualitative sign cannot be obtained in animal models other than by careful behavioral evaluations (e.g. disorientation, ataxia).
To support interpretation, video recording concomitant to EEG monitoring allows for observation of premonitory signs of seizure (e.g. salivation, emesis, ataxia, tremors) (Podell, 2010) that are not otherwise captured by EEG recording alone. In addition, the margin between plasma exposure at onset of premonitory clinical signs, and at seizure onset, can be measured and serves to evaluate the risk associated with the drug candidate. Observation of such premonitory signs in clinical trials will often halt dosing. The onset of adverse effects is unpredictable and restraining an animal for an extended period of time (i.e. several hours) is not feasible or ethical. In fact, restraint has been shown to lower seizure threshold during seizure susceptibility studies (Swinyard, Radhakrishnan, & Goodman, 1962) . Continuous video-EEG monitoring by telemetry can be an alternative to monitor freely moving animals, therefore decreasing the potential for stress-related artifacts or changes in seizure threshold.
The current study aimed to present representative EEG results obtained by telemetry combined with video in conscious Beagle dogs, cynomolgus monkeys and Sprague-Dawley rats after determination of the pentylenetetrazol (PTZ)-induced seizure threshold. Our hypothesis was that the Beagle dog would be more sensitive to PTZ both on the seizurogenic dose and premonitory clinical signs determination. Moreover, quantitative EEG spectral changes (qEEG) considered as an advanced analysis strategy was undertaken in rats and monkeys to illustrate methodologies to screen for drug-induced stimulatory or neuro-depressive effects. Doses of non-seizurogenic drugs used for qualification of qEEG were selected to induce slight to moderate effects based on historical data (unpublished). These results are discussed in the context of seizure liability study design and interpretation.
Materials and methods

Statement on use and care of animals.
During the study, care and use of animals were conducted in accordance with principles outlined in the current Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (National Research Council, 2011) . CiToxLAB North America's facility is AAALAC accredited. All procedures were conducted as per Standard Operating Procedures (SOPs) and with approval and overview of the institutional animal care and use committee.
2.2. Animal housing and preparation.
Beagle dog and cynomolgus monkey models
The animal room environment was controlled (temperature 21 ± 3°C, humidity 30%-70%, 12 h light, 12 h dark, 10-15 air changes per hour) and temperature and relative humidity were monitored continuously. Five (5) Beagle dogs and twelve (12) cynomolgus monkeys were used to generate representative data with the model, and their response to the positive control drug (PTZ) (see the Experimental methods section). At onset of treatment, Beagle dogs were 10 months old and cynomolgus monkeys were 2 years old.
Prophylactic antibiotics (Baytril, Bayer Health Care, Toronto, ON, Canada; 0.1 mL/kg, 50 mg/mL; Penicillin G procaine, Vetoquinol, Lavaltrie, QC, Canada; 0.4 mL, 300 000 IU/mL) were administered by intramuscular (IM) injection prior to surgery and daily for at least two days. Preemptive analgesia was attained via a transdermal Fentanyl patch (Sandoz, QC, Canada; 12.5 μg/h) over three days. An antibiotic, Cefazolin (Novopharm, Markham, ON, Canada; 0.4 mL/kg, 80 mg/mL) was applied to the skull surgical site. A local anesthetic (Bupivacaine, Hospira, Montreal, QC, Canada, 0.25%, 0.5 mL; or Lidocaine, Vetoquinol, Lavaltrie, QC, Canada; 20 mg/mL, 0.5 mL) was injected (0.1-0.2 mL) in 6-10 subcutaneous (SC) sites distributed over the skull surgical site to ensure a multimodal analgesia. Animals were placed on a heating pad and inhaled a mixture of oxygen (O 2 ) and isoflurane (AErrane, Baxter Corporation, Mississauga, ON, Canada). Respiratory rate was maintained between 8 and 20 breaths/min with an inspiratory airway pressure between 18 and 25 cm H 2 O using a mechanical ventilator (Hallowell EMC, Pittsfield, MA, USA). Heart rate, pulse oximetry (SpO 2 ) and body temperature were monitored continuously during anesthesia. A longitudinal incision was performed lateral but close to the linea alba, and the internal abdominal oblique muscle was separated from the aponeurosis of the transversus abdominis. The telemetry transmitter was placed between the internal abdominal oblique muscle and the aponeurosis of the transversus abdominis muscle. The rectus abdominis was sutured with a simple continuous suture and EEG electrodes were tunneled subcutaneously to a small skin incision in the neck. Electroencephalographic leads (TL11M2-D70-EEE, Data Science International, St.-Paul, MN, USA) were secured on to the skull bones to monitor three standard bipolar derivations (C3-O1, C4-O2 and Cz-Oz) using the 10-20 electrode system. A linear groove was done in the cranial cortical bone to secure the electrodes with surgical glue (Vetbond, 3M, St-Paul, MN, USA) and acrylic. Electromyographic (EMG) recording was obtained using electrodes sutured to longitudinal muscles in the neck area and recorded continuously with the telemetry transmitter. A period of three weeks was allowed between surgery and the start of experimental procedures.
An additional ten (10) cynomolgus monkeys (3.5-6 years old), maintained under the same environmental conditions as described above, were surgically prepared with the same telemetry transmitters (TL11M2-D70-EEE, Data Science International, St.-Paul, MN, USA). The leads were placed to monitor standard bipolar derivations (F3-C3, C3-O1, C4-O2 and/or Cz-Oz). These animals were used for the caffeine challenge (as detailed subsequently in 2.3 Experimental methods) with qEEG spectral analysis (see below).
Sprague-Dawley rat model
A telemetry transmitter (TL11M2-C50-PXT or F40-EET, Data Science International, St.-Paul, MN, USA) for EEG monitoring was used with one standard bipolar derivation (Fz-Oz) in forty nine (49) adult rats. Animals were aged 9 to 14 weeks old. The animal room environment was controlled (temperature 21 ± 3°C, humidity 30%-70%, 12 h light, 12 h dark, 10-15 air changes per hour) and temperature and relative humidity were monitored continuously.
Penicillin G procaine (Vetoquinol, Lavaltrie, QC, Canada, 1.0 mL, 300 000 IU/mL) was administered SC once daily for three days beginning on the day of surgery. Buprenorphine (Champion Alstoe, Whitby, ON, Canada, 0.04 mL, 0.3 mg/mL) was administered twice daily for three days. Local anesthetics (Bupivacaine, Hospira, Montreal, QC, Canada, 0.25%, 0.1 mL; Lidocaine, Vetoquinol, Lavaltrie, QC, Canada, 20 mg/mL, 0.1 mL) were injected in 4 SC sites distributed over the skull surgical site. The animal was placed on a heating pad and inhaled a mixture of O 2 and isoflurane. A longitudinal incision was performed on the linea alba, and a telemetry transmitter was secured in the abdominal cavity. Both EEG and EMG electrodes were tunneled subcutaneously to a small skin incision in the neck. The abdominal skin incision was closed with interrupted buried sutures and the animal was placed in sternal recumbency to expose the skull for the remainder of the surgery. The EEG leads were secured on the cranial bone to monitor one bipolar derivation while EMG leads were sutured to longitudinal muscles of the neck. A linear groove was done in the cranial cortical bone to secure the electrodes with surgical glue (Vetbond, 3M, St.-Paul, MN, USA) and acrylic. A period of three weeks was allowed between surgery and the start of experimental procedures.
An additional twenty-four (24) Sprague-Dawley rats were used to illustrate the qEEG response to PTZ infusion as described subsequently in Experimental methods.
Experimental methods.
Physiological data monitoring
Electroencephalographic data were obtained from animals using telemetry transmitter leads using bipolar derivations (Monkey: F3-C3, C3-O1, C4-O2 and/or Cz-Oz; Dog: Cz-Oz and C4-O2; Rat: Fz-Oz). The EEG, and EMG, were recorded continuously from at least 24 h prior to dosing to at least 24 h post-dosing completion (Dataquest ART, Data Science International, St.-Paul, MN, USA). The EEGs were subjected to computer analysis from at least one hour pre-dosing to at least 24 h post-dosing (NeuroScore, Data Science International, St.-Paul, MN, USA). Digital color cameras (Geovision, Irvine, CA, USA), with daylight and infrared night vision connected to a computerized system (IBM Intellistation Z pro, Xeon 3.8 Ghz, 3.5 TB hard drive, New Orchard Road Armonk, NY, USA), were used for behavioral video monitoring.
Cynomolgus monkey
Pentylenetetrazol (50 mg/mL) was administered at a dose rate of 40 mg/kg/h by intravenous (IV) infusion at a rate of 10 mL/h in twelve (12) monkeys, until convulsion onset and the infusion was stopped immediately. Diazepam (Sandoz, Boucherville, QC, Canada; 1.0 mg/kg) was administered IV at seizure onset.
A caffeine challenge was conducted using a prospective, randomized, controlled, crossover study to illustrate applications of qEEG in drug development. Caffeine (10 mg/kg, IM) was administered approximately 10 min prior to lights off to ten (10) animals (i.e. at 18:00). Sterile saline USP was administered as a control. A wash-out of at least 3 days was allowed between each treatment.
Beagle dog
Pentylenetetrazol (50 mg/mL) was administered at a dose rate of 100 mg/kg/h by IV infusion to five (5) dogs, until the start of convulsions and was then stopped immediately. Diazepam (1 mg/kg, IV) was administered immediately following seizure onset.
Sprague-Dawley rat
Both EEG and EMG were recorded following saline IV infusion in rats (n = 49) or IV PTZ infusion (cross over design with n = 8). Three (3) rats were used to illustrate qEEG effects of diazepam (3 mg/kg, IM) and amphetamine (3.75 mg/kg, PO).
Twenty-four (24) rats received a PTZ (8 mg/mL) IV infusion at a dose rate of 288 mg/kg/h. Diazepam (2-6 mg/kg) was administered by intra-peritoneal (IP) injection following tonic convulsion onset.
-Sixteen (16) Sprague-Dawley rats were used to illustrate the effect of yohimbine (18 mg/kg, SC, 8 min prior to PTZ infusion) as a positive control (n = 8) in the PTZ seizure threshold model, with an equal number of animals (n = 8) receiving either yohimbine or saline (control). -Eight (8) Sprague-Dawley rats received phenobarbital (n = 4, 30 mg/kg, IP) or saline (n = 4, same volume) in the same seizure threshold model initiated 30 min after phenobarbital/saline administration.
Electroencephalographic analysis methods.
The EEG and EMG (when applicable) traces were analyzed using manual and automated detection (NeuroScore, Data Science International, St. 
Statistical analysis.
For each parameter, a one-way analysis-of-variance (ANOVA) was conducted and the residuals were saved. Gaussian distribution was evaluated using the Shapiro-Wilk test on residuals. Whenever the Shapiro-Wilk test was found to be significant (p ≤ 0.001) then the data were transformed and re-submitted to the analysis. The Levene test was used to examine the homogeneity of group variances. For the ANOVA model, if the overall group differences were shown significant (F-Test), then pair-wise comparisons were conducted using Tukey's test. Data are presented as mean (SD).
Results
The EEG and EMG (when applicable) electrodes were well tolerated in all animals.
3.1. Cynomolgus monkeys 3.1.1. Seizure assessments Premonitory seizure signs observed during the pre-ictal period with associated average PTZ doses are listed in Table 1 . Emesis and decreased activity were the most common clinical signs followed by hypersalivation and ataxia. Excessive vocalization, repeated yawning, excessive scratching were also observed. Tonic and/or clonic convulsions were noted approximately 81 min following the start of PTZ infusion and lasted an average of 120 (83) s, corresponding to a PTZ dose of 56.1 (12.7) mg/kg. The Fig. 1A illustrates EEG ictal activity measured in the cynomolgus monkey at the onset of seizure activity including EEG sharp waves and spike trains. Fig. 1B demonstrates EEG activity throughout the ictal period including post-ictal power attenuation.
Several clinical signs, including hypersalivation, decreased activity and ataxia were observed up to 52 min post-ictus.
Spectral analysis (power bands and qEEG)
Pre-ictal spectral changes compared to baseline data reveal an increase in the higher frequency power bands (i.e. theta to beta) just prior to and during the PTZ induced ictal period (Fig. 2) while the low frequency delta band is not modified.
As noted in Fig. 3 , spectral analysis showed changes across a large range of frequencies (0.5-127 Hz) following caffeine administration (10 mg/kg, IM) when compared to time-matched data obtained following administration of saline (negative control). Decreases in low range frequencies (0.5-13 Hz) and increases in higher frequencies (N14-127 Hz) were observed with effects dissipating progressively over 12 h following dosing.
3.2. Beagle dogs.
Seizure Assessments
The Fig. 4 illustrates EEG during ictal activity in a Beagle dog following PTZ IV infusion. Table 2 presents the averaged PTZ doses at onset of premonitory signs including uncoordination/ataxia, excessive vocalization and emesis noted as early as 18 min prior to PTZ-induced seizure. Additional clinical signs, such as hypersalivation, head shaking, excessive Fig. 1 . A) EEG at seizure onset in a cynomolgus monkey following PTZ infusion (40 mg/kg/h, IV) including EEG sharp waves and spike train. B). EEG activity from a representative ictus in a cynomolgus monkey following PTZ infusion (40 mg/kg/h, IV) with characteristic post-ictal attenuation of power across the entire spectrum. 
Spectral analysis (power bands and qEEG)
Spectral analysis revealed important changes in a large range of frequencies (i.e. 0.5-50 Hz). More specifically, when compared to values prior to PTZ infusion, considerable increases in all power bands were observed just prior to seizure onset (Fig. 5) Premonitory seizure signs observed during the pre-ictal period with associated average PTZ doses are listed in Table 3 . Tremors were observed in 75% of the animals prior to seizure. In Sprague-Dawley rats (13 to 14 weeks of age), clonic and tonic convulsions were noted respectively 10.3 (2.4) and 19.4 (2.8) min following the start of PTZ infusion, corresponding to respective PTZ doses of 49.4 (11.7) and 93.3 (13.3) mg/kg. Myoclonic jerks were observed following a PTZ dose of 43.8 (5.5) mg/kg. Fig. 6 illustrates EEG and EMG activity in a Sprague-Dawley rat during representative repetitive sharp waves.
Phenobarbital, administered 30 min prior to the start of PTZ infusion, increased the dose required to reach tonic convulsions (Fig. 7) . In contrast, yohimbine (SC) reduced the dose of PTZ required to elicit myoclonus, clonic and tonic convulsions (Fig. 8) . Yohimbine given as an IV bolus (12 mg/kg) induced spontaneous seizure in most animals (62.5%) and significantly reduced the PTZ threshold to paroxysmal EEG activity and onset of clonic convulsions (p b 0.05).
Following diazepam (3 mg/kg), spectral analysis confirmed important increases in high frequencies (40-120 Hz) with peak increases at 73.5 (14.8) min at a frequency of 115 Hz, a phenomenon termed pharmacological dissociation. At qEEG, amphetamine (3.75 mg/kg, PO) increased high frequencies (approximately 40-120 Hz) and decreased low frequencies (1-14 Hz) as illustrated in Fig. 9 .
Discussion
The human elderly population is associated with a sharp increase in the incidence of epilepsy due to the influence of conditions such as stroke, brain tumors, and aging-related neurodegenerative disorders (Loiseau et al., 1990; Wallace, Shorvon, & Tallis, 1998) . In parallel, the elderly population is exposed to more prescription drugs than any other age group. As a well-established proconvulsant agent, PTZ is used to assess potential changes in seizurogenic threshold (Löscher, 2009 ). This agent is used to identify pro (anti) convulsant drugs by a decrease (increase) in the PTZ dose required to reach seizure onset.
PTZ seizurogenic threshold test represents a valuable model as part of seizure risk assessment in drug development in all species but some limitations also exist. A number of compounds recognized to induce seizure act by mechanism of action which differ from PTZ. The latter is recognized to be a noncompetitive antagonist of the γ-aminobutyric acid (GABA) A receptor complex (Hansen, Sperling, & Sánchez, 2004; Huang et al., 2001 ). In such case, the PTZ seizure threshold test may not reflect the seizure risk of the drug. As a result, seizure liability testing will typically include EEG evaluations after the drug alone as a primary safety testing component and possibly in combination with PTZ to assess seizure threshold. Repeated seizures may lower the seizure threshold, a phenomenon identified as kindling, which was demonstrated with PTZ (Gilbert & Goodman, 2005) . As a consequence, repeated administration of seizurogenic agents such as PTZ is discouraged in non-clinical seizure assessments. Similarly, a non-convulsant dose administered once may induce seizures when administered repeatedly (White, Porter, & Kupferberg, 2008; Wilke, 2011) possibly due to drug accumulation or delayed neurotoxicity. No single preclinical safety testing strategy can apply to all compounds and identification of acute or chronic drug effects may be warranted (Ferrero et al., 2005) . Designing seizure assessment studies requires a careful evaluation of multiple facets including pharmacology, pharmacokinetics/biodistribution, the target indication and patient populations, regulatory requirements/expectations, species specificity and projected clinical trial designs, to list only a few. Within an animal species, variations in susceptibility to drug-induced seizure need to be considered to determine the optimal group size. The incidence of CNS adverse events in prior toxicology/pharmacology studies may inform on expected inter-individual variations and the group size and/ or doses to be tested in the follow-up seizure liability study need to reflect this anticipated incidence. Typically, group sizes of 5-10 are used in rodents while 4-8/group is often adequate in non-rodents. The progression of clinical signs to seizure in animals is typically used to inform premonitory signs that are later used to halt dosing in clinical trials. It remains that the presence and sequence of premonitory signs in animals may differ from that observed in humans and caution is recommended in the translational assumptions. When present, discrepancies between the progression of premonitory signs in animals compared to humans may be caused by differences in receptor binding affinity, cellular mechanisms, metabolism, biodistribution, just to name a few. Species specificity may also impact the clinical sign profile observed prior to seizure (e.g. lack of emesis in rats, high susceptibility to emesis in dogs). When convulsions are observed in prior nonclinical studies, the follow-up neurological safety pharmacology study may or not evaluate dose levels high enough to induce seizure. As the objective of such follow-up study is to confirm the no observed adverse effect level (NOAEL) relative to seizure activity, an appropriate safety margin (e.g. 10×) is required but dose levels considerably higher than intended clinical doses may not be relevant even when such dose levels were used in early dose range finding toxicology studies. Interactions with regulators reviewing the safety data may guide in selecting the most relevant non-clinical neurotoxicity testing strategy. When communication with regulators is not possible, scientific justifications (e.g. targeted indication, context of use) can be used to support design selection.
The observation of moderate to severe tremors in a toxicology study may trigger neurological safety concerns and understanding the nature of those tremors presents value in completing the risk assessment. Enhanced physiological tremors occur in healthy individuals (Sturman, Vaillancourt, & Corcos, 2005) , are usually reversible and are generally not associated with seizure activity. Enhanced physiological tremors may be amplified by anxiety or fear and are visible to the naked eye (National Institute of Neurological Disorders and Stroke, 2012a, 2012b) . Essential tremors occur during voluntary muscle contractions and may also be triggered by stress or fear or by drugs including neuroleptics, cyclosporines, and β 2 adrenergic agonists (Crawford & Zimmerman, 2011; van Harten, Hoek, Matroos, Koeter, & Kahn, 1998) . Essential tremors may be associated with a mild dysfunction of the cerebellum (Bhidayasiri, 2005) . Intention tremors occur during directed movement, result from a dysfunction of the cerebellum (Bhidayasiri, 2005) and can be caused by trauma, tumor, stroke, infection but also toxicity. Antiarrythmic agents, benzodiazepines and cyclosporins are reported to cause intention tremors (Crawford & Zimmerman, 2011) . In drug development, an expert neurologist is typically not present in the animal room to evaluate tremors at the time of occurrence. In this context, synchronized highresolution video-EEG may be useful to investigate the potential correlation between tremors and abnormal EEG activity but also to define the nature of tremors and finally assess any safety concern. Tremors are observed relatively commonly prior to seizure onset in non-rodents, including dogs and non-human primates but also in most rats as observed in the current study. While video monitoring is generally useful, it may not capture subtle premonitory clinical signs such as nystagmus, facial twitches or high frequency tremors and the presence of an expert observer at selected timepoints (e.g. around T max ) can be valuable in some cases. Clinical observations including ataxia, head shaking, nystagmus, head tilt and nausea/vomiting can be signs of a drug induced vestibular syndrome. Approved drugs such as metronidazole may elicit signs of vestibular toxicity (Sammut, 2010) . As clinical manifestations of a vestibular syndrome may be similar to pre-ictal and ictal related clinical signs to technical staff, EEG monitoring can serve to differentiate seizures from drug-induced vestibular toxicity. The distinction between these two clinical conditions (vestibular toxicity vs. seizure) has a major impact on risk assessment as seizures are recognized as life-threatening adverse events and a vestibular syndrome is not.
In addition to video-EEG, toxicokinetic (TK) evaluations generally constitute an important component of non-clinical seizure liability testing. Doses allowed in clinical trials will initially be limited by the human equivalent of the animal plasma concentrations that were achieved at the highest safe dose. The TK investigations will aim to capture plasma levels at seizure onset, around premonitory clinical signs, but also in the absence of abnormal EEG or clinical signs (i.e. at NOAEL). Systemic and CNS drug exposure following oral administration often present greater variability than parenteral routes which may justify an increased TK schedule in seizure liability studies with this treatment route. In large animals, a more intensive TK schedule can be used to interpret CNS data in light of individual drug exposure levels. In seizure liability studies conducted in rodents, inclusion of a satellite TK group to confirm drug exposure can be valuable to avoid any impact the blood collections and/or animal restraint on EEG activity. To facilitate interpretation of video-EEG data, continuous IV infusion of the test compound may allow calculation of the plasma drug concentration at each critical observation (e.g. onset of premonitory signs, first myoclonic activity, seizure onset, etc.). The advantages of a progressive well-controlled increase in plasma level may justify the use of an IV dosing in seizure liability studies, even if the intended route of administration of the compound is oral.
According to the ICH S7A Guideline (2001), "consideration should be given to the selection of relevant animal models or other test systems so that scientifically valid information can be derived". As Beagle dogs are known to be overly sensitive to idiopathic epilepsy (Edmonds et al., 1979; Hoskins, 2000) , described as a genetic disease in this breed (Sargan, 2004) , the use of Beagle dogs presents caveats for seizure risk assessment in non-clinical studies. In the present study, the IV PTZ dose inducing clonic convulsions in Beagle dogs was 36.1 (3.8) mg/kg compared to 56.1 (12.7) mg/kg in cynomolgus monkeys and 49.4 (11.7) in Sprague-Dawley rats. Some research Beagle dogs present idiopathic epilepsy, where convulsions are noted in the absence of drug treatment. The interictal short time EEG evaluations performed in dogs with confirmed idiopathic epilepsy was normal in more than 2/3 of the animals and was not considered a useful screening method (Brauer et al., 2012) . In this context, pre-study EEG may not be sufficient to detect a genetic predisposition to lower drug induced seizure threshold. In another study, EEG monitoring under anesthesia revealed high frequency and low amplitude paroxysmal discharges in most dogs confirmed to present idiopathic epilepsy (Jaggy & Bernardini, 1998) . As with other species, considerable variability exists among individual dogs, which further complicates the use of a breed with documented genetic susceptibility. Table 4 presents data obtained in similar conditions and supports the relatively high susceptibility of Beagle dogs to PTZ induced myoclonus, clonic and tonic convulsions compared to cynomolgus monkeys and Sprague-Dawley rats. In previous studies, the dose of PTZ administered as SC boluses until convulsions in cynomolgus monkeys was reported to be 70 (17) mg/kg (Authier et al., 2009 ). Similar to results from the current study, PTZ convulsive doses in conscious or anesthetized Beagle dogs were reported at 34 (2) and 36 (5) mg/kg IV, respectively (Dürmüller et al., 2007; van der Linde et al., 2011) . In Sprague-Dawley rats, PTZ at 50 mg/kg (IP) induced seizure and overt convulsions (DeBoer & Friedrichs, 2009 ). Similar to our results, the PTZ threshold for clonic convulsions with IV infusion in SpragueDawley rats was 59 (3) mg/kg (Mirski, Rossell, McPherson, & Traystman, 1994) . In contrast, the convulsion threshold dose in adult (8 weeks) Wistar-Unilever was reported to be much lower at 21.3 ± 2.6 mg/kg (Himmel, 2008) suggesting differences between rat strains. The murine PTZ threshold model is usually associated with higher doses to induce clonic (70 mg/kg) and tonic (130 mg/kg) convulsions (CD-1 mice; Mandhane, Aavula, & Rajamannar, 2007) . Cynomolgus monkeys are used as a large animal species as they lack the genetic predisposition to seizure aforementioned but also present genetic polymorphism closer to the human population (Higasino et al., 2009; Watanabe et al., 2007) . Cynomolgus monkeys may be useful to identify seizure potential of some pharmaceutical candidates when rats failed to identify seizure activity (Markgraf, DeBoer, & Cirino, 2010) making the non-human primate a valuable model in some circumstances. In comparison to the non-human primate, whose prefrontal cortex layers are well-defined (Fuster, 2008 ) the cytoarchitechture of the dog prefrontal cortex appears more primitive, partly due to the vague separation between the prefrontal and motor cortexes (Kosmal, Stepniewska, & Markow, 1983) . The growth of the prefrontal cortex and granularization of layer IV (internal granular layer) are characteristic in non-human primates as well as in humans (Fuster, 2008) . While few double bouquet cells are present in carnivores compared to primates (10 vs hundreds in a~25 mm histological section), these cells, which are yaminobutyric acid (GABA) containing interneurons, are completely absent in rodents (Yáñez et al., 2005) . In addition, there are a greater number of GABAergic neurons in the non-human primate and human in comparison to the rat (Yáñez et al., 2005) . Finally, as in the human neocortex, there are hundreds of inhibitory networks established from each double bouquet cell in the non-human primate (Yáñez et al., 2005) . When further considering species selection, the argument that the most sensitive species should be preferred in safety assessments may be rejected when seizures are noted in Beagle dogs on the basis of the poor translational potential of this species and the risk of discontinuing development of a drug candidate that would otherwise be shown as safe at doses that are clinically effective in humans. It remains that situations where humans are more sensitive than the Beagle dog to druginduced seizure were reported (unpublished personal communications) and selection of the test species should be done carefully and in conjunction with regulators, when possible. Whenever the clinical risk of drug-induced seizure is considered important or insufficiently characterized, video-EEG may be required in subsequent clinical trial(s) with a major impact on costs. In this context, non-clinical seizure liability studies may reduce overall drug development costs and ensure that drugs are advanced in the clinic at doses demonstrated to be safe in relevant models.
From a clinical perspective, confirmation that drug-induced seizures are self-limiting and that conventional anti-convulsive drugs (e.g. diazepam, phenytoin or propofol) can successfully treat drug-induced seizure can be of importance. Low safety margins between the anticipated efficacious plasma concentration and plasma levels that have induced seizure in some animals further increase the relevance of emergency seizure treatment confirmation.
Interpretation of video-EEG data will typically be undertaken using automated detection of seizure activity (Authier et al., 2009; White et al., 2006) combined with manual and qualitative review of EEG by an expert. When using automated tools, a preference is given for high sensitivity over specificity to minimize the incidence of false negative events. False positive activity can be classified during manual qualitative review of EEG. Interrater agreement is recognized to be high for cases with frank seizures as observed with epilepsy (Benbadis et al., 2009) . Several features of EEG traces facilitate identification of generalized seizure events including postictal depression characterized by an increase in slow low voltage activities (Kaufman, 2006) . It remains that interobserver discrepancies in EEG interpretation are reported (Walczak, Radtke, & Lewis, 1992) especially for more subtle changes suggestive of altered seizure threshold. This highlights the importance of using baseline/pre-drug and time-matched EEG data as a reference for each individual during interpretation of post-dosing EEG traces. Abnormal EEG traces are often associated with behavioral manifestations. Consequently, qualitative EEG review at times when selected behavioral changes (e.g. tremors, myoclonus, ataxia, asymmetric posture, facial twitches, stupor, etc.) were noted is common as part of data interpretation. In some cases, telemetry implantation for EEG monitoring may interfere with the primary scientific endpoints as would be the case in general toxicology studies where histopathology is performed on an exhaustive list of organs. Surgical implantation of a telemetry transmitter may induce histopathological changes and is typically avoided in general toxicology. Surface EEG monitoring at selected timepoints for 10-30 min at each occasion based on available pharmacology data represents an alternative strategy to investigate seizure liabilities in toxicology studies. When using surface EEG electrodes, the addition of EEG monitoring immediately upon identification of selected abnormal clinical signs may increase sensitivity of the safety assessments.
While the primary objective of video-EEG monitoring can be seizure liability testing, this model can be used to quantify neuro-stimulatory or neuro-depressive effects of drugs on brain activity simultaneously. As illustrated following caffeine in the cynomolgus monkey (Fig. 3 ) and amphetamine and diazepam in the Sprague-Dawley rat (Fig. 9) , qEEG can be used to detect pharmacological neuromodulation. Moreover, we observed an increase in both beta and gamma power bands following administration of diazepam in rats despite its sedative properties (Van Lier, Drinkenburg, van Eeten, & Coenen, 2004) , a phenomenon well characterized with this drug and known as pharmacological dissociation (Jongsma, van Rijn, van Egmond, van Schaijk, & Coenen, 2000) . Using the percent change in power from a time matched period with vehicle/ control dosing in the same animals can allow for a rapid and sensitive screening of potential neuropharmacological effects on qEEG. Analysis over the entire spectrum of individual EEG frequencies (e.g. 1 Hz increments from 1 to 130 Hz) allows for finer assessment in pharmacological trends (Figs. 3 and 9 ) than would be achieved with power bands only. When qEEG becomes of importance in a study, appropriate designs would typically include a cross-over administration. In addition, animals receiving different doses including control should be housed in different rooms or scheduled for dosing on different days to avoid "acrossthe-room" qEEG interferences from excitation or sedation. As one would expect, animals receiving a dose of neuro-stimulant will cause an increase in qEEG values from neighbor animals receiving control only. Finally, state-of-the-art qEEG will often include repeated administration(s) of each treatment (drug levels and control) after an appropriate wash-out to confirm reproducibility, increase sensitivity and enhance interpretation through discrimination of individual patterns of change.
It remains that the sensitivity of EEG monitoring is not absolute. Brain activity obtained from electrodes placed at the skull surface reflects the summation of complex neuronal activity in the multiple layers of the cortex and other brain structures (Smith, 2005) . Seizure activity may not always be represented on EEG tracings. Approximately 10% of patients with epilepsy were reported not to show EEG depolarization (Smith, 2005) . Despites potential limitations, continuous video-EEG with EMG monitoring is considered to be a useful tool to evaluate seizure liabilities and neuromodulatory effects in various species during drug development.
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